Results Recap: Medtronic's Valiant Navion Earns FDA Approval Based On 30-Day Results
Results Recap is Medtech Insight's exclusive summary of clinical trial results that have been announced or published in the past week, based on information collected by Meddevicetracker. This week's edition covers the week of Oct. 19 - Oct. 25, including trial announcements from Medtronic, iCAD, PharmaEngine, Inc., Nanobiotix SA, and Myriad Genetics.
You may also be interested in...
Recall Of Valiant Navion Could Cost Medtronic $40M
The company ordered the recall after three stent fractures and a death occurred in an 89-participant clinical trial.
2018 Earnings Spotlight: Transcatheter Valve Repair Remains Big Drivers For Medtronic, Edwards, Abbott
Reported sales and earnings from the publicly traded cardiovascular device companies in 2018 were generally strong, led by transcatheter aortic valve replacement devices, but some sectors of the industry, especially ventricular assist devices and peripheral drug-coated balloons, face significant challenges. Here's a recap of results from the cardio device companies that have reported so far, with a focus on Medtronic, Edwards, and Abbott.
News We’re Watching: SALSA Reintroduced, FDA Approves Abbott Valve, Metallic Implant Study
A bill aimed at preventing laboratory reimbursement cuts has been reintroduced in the US Congress. Additionally, an Abbott valve landed FDA approval, On Target Labs reported trial results, and the FDA warned that dental palate expanders may pose health risks to adults.